ArticleNature communications2025
Multiomics insight into disease trajectories of cardiometabolic diseases and cancer.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Multi-omics profiles of sex hormone-binding globulin are associated with subclinical atherosclerosis in men with HIV.Genome medicine · 2026Article
- Artificial intelligence-empowered, clinically-integrated multiomics research in thrombosis: a call to action.Research and practice in thrombosis and haemostasis · 2026Article
- Dissecting the Gut Microbiota-metabolite-coronary Atherosclerosis Axis: Evidence from Two-sample Mendelian Randomization.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Artificial intelligence in cardio-oncology: decoding mechanisms, predicting toxicity, and personalizing cancer therapy.Frontiers in cardiovascular medicine · 2026Review
- Cardiometabolic comorbidities and prostate cancer risk: evidence from the prostate, lung, colorectal, and ovarian cancer screening trial.Frontiers in oncology · 2026Article
- Multiomics insight into disease trajectories of cardiometabolic diseases and cancer.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multimorbidity of cardiometabolic disease (CMD) and cancer is a growing but understudied global challenge in an aging world. Here, we perform multistate analysis in 429,555 UK Biobank participants to investigate transition patterns, identify multiomics signatures, and construct prediction models from baseline to single and multiple morbidities. During a median follow-up of 15 years, 105,903 participants develop single morbidity and 15,088 develop multimorbidity of CMD and cancer. Participants with multimorbidity have a 13%-33% higher mortality probability than those healthy or with single morbidity. In individuals living with multimorbidity, the development of CMD before cancer presents a higher mortality risk than the reverse order. Distinct and shared multiomics signatures are identified, with proteomics scores outperforming other omics in predicting disease trajectories (ΔC-statistic vs. base model: 0.03-0.14). This study reveals distinct transition patterns in CMD-cancer multimorbidity cluster and develops potentially useful prediction tools for supporting risk management if externally validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.